Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Effective Collaboration - Team Research for Better Returns: -- Ignore unavailable to you. Want to Upgrade?

To: The Ox who wrote (3769)	11/17/2014 8:59:17 AM
From: The Ox	Read Replies (1) \| Respond to of 8253

Roth Capital boosts its price target on Celldex Therapeutics (Nasdaq; CLD) from $40 up to $43 and affirms its Buy rating after the company offered statistically significant data from Phase 2 ReACT study of rindopepimut in EGFRvIII-positive glioblastoma (GBM) at SNO last week. Analyst Joseph Pantginis comented, We are very impressed with the overall survival data in the bevacizumab-naive patients, especially that rindo represents the first true indication of a survival benefit in this indication. Recall that Avastin (bevacizumab) was approved on response rate previously and has not shown a survival benefit. Rindo has been somewhat on the sidelines of investor focus, in our belief, based on the wait for ACT IV data. These ReACT data should change this quickly. In our belief, rindo could represent the second cancer vaccine approved in the U.S. following the commercial failure of Dendreon's (DNDN-Sell) Provenge. For an analyst ratings summary and ratings history on Celldex Therapeutics click here. For more ratings news on Celldex Therapeutics click here. Celldex Therapeutics closed at $14.16 yesterday.